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Clinical Infectious Diseases
MAJOR ARTICLE

Quantitative Human Immunodeficiency Virus (HIV)-1
Antibodies Correlate With Plasma HIV-1 RNA and
Cell-associated DNA Levels in Children on Antiretroviral
Therapy
Margaret McManus,1, Jennifer Henderson,1 Anita Gautam,1 Robin Brody,1 Eric R. Weiss,1 Deborah Persaud,2 Eric Mick,3 and Katherine Luzuriaga1; and
the PACTG 356 Investigatorsa
1

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester; 2Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins University School of Medicine,
Baltimore, Maryland; and 3Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester

Background. This study measured serial plasma human immunodeficiency virus (HIV)-1–specific antibody (Ab) levels in children who initiated antiretroviral therapy (ART) prior to 2 years of age, and evaluated their relationship to peripheral blood HIV-1
RNA and DNA levels.
Methods. We studied 46 HIV-1–infected children, stratified by age at ART initiation (<3 mo, early therapy [ET]; >3 mo–2 years,
late therapy [LT]) and by virologic response (R) or non-response (NR), before and up to 4 years following ART. We studied 20
HIV-1–uninfected children born to HIV-1–infected mothers (seroreverters [SR]) as controls. Plasma immunoglobulin G (IgG) Ab
levels directed against HIV-1 envelope (gp160, gp41), gag (capsid, p24; matrix, p17), reverse transcriptase (p66/51), and integrase
(p31) were serially measured using quantitative enzyme-linked immunosorbent assays. HIV-1 Ab rates of decline were estimated
over the first 15 months of the study.
Results. The HIV-1 Ab rates of decline in the ET-R group were similar to those in the SR group for all Ab specificities, except for
p17 (P = .01). Ab decline rates in the LT-R group and the NR group were significantly slower than in the SR group for all tested Ab
specificities. After 1 year of age, Ab levels to p31 and p17 were significantly associated with HIV-1 RNA levels (P < .001); Ab levels to
gp160 (P < .001) and gp41 (P < .001) were significantly associated with cell-associated HIV-1 DNA levels.
Conclusions. Quantitative HIV-1–specific Ab levels may be useful for screening children on ART for viral suppression or for
residual, cell-associated HIV-1 DNA levels.
Clinical Trials Registration. NCT00000872.
Keywords. pediatric early antiretroviral therapy; HIV-1 persistence; HIV-1 quantitative antibodies.
Combination antiretroviral therapy (ART) markedly reduces
human immunodeficiency virus (HIV)-1–related morbidity
and mortality in children [1]. Early ART initiation in children prior to 3–6 months of age can be particularly effective
for long-term control of HIV-1 replication, preserving immune functions [2, 3], reducing HIV-1–related illnesses and
mortality [4], and limiting residual HIV-1 reservoirs [5, 6].
International treatment guidelines [7–9] now recommend
ART initiation in HIV-1–infected children as soon as possible
after birth.
Methods for quantifying plasma HIV-1 RNA and peripheral
blood mononuclear cell (PBMC)-associated HIV-1 DNA
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in children following ART are expensive and logistically
challenging, particularly for implementation in limitedresource settings. We [10] and others [11–13] have previously
shown that children who achieve durable suppression of HIV-1
replication after early (<3 months) ART have very low levels of
PBMC-associated HIV-1 DNA, and the majority lack persistent
HIV-1 immunoglobulin G (IgG) antibodies [3, 14]. Children
who initiate treatment after 3–6 months of age have higher
levels of PBMC-associated HIV-1 DNA and remain HIV-1–
antibody (Ab) positive. In a prior cross-sectional study, children
with negative or indeterminate Western blots had lower levels
of circulating HIV-1 DNA than those with positive Western
blots [15]. We therefore undertook this study to further evaluate
the utility of using quantitative HIV-1 Ab levels to HIV-1
proteins as a screening method for virologic suppression and
residual PBMC-associated HIV-1 DNA in children on therapy.
The quantitation of Ab levels to selected HIV-1 proteins prior
to and sequentially up to 4 years following ART allowed for
the calculation of Ab clearance rates and the development of
models that used specific Ab levels to predict the likelihood
HIV-1 Antibodies and Viral Persistence • CID 2019:68 (15 May) • 1725

of undetectable plasma HIV-1 RNA or the level of circulating,
PBMC-associated HIV-1 DNA.
METHODS
Study Cohort

The study cohort included 46 HIV-1–infected children, stratified
by timing of ART initiation (early therapy [ET] <3 months of age;
late therapy [LT] >3 months to 2 years of age) and as virologic
responders (R) or non-responders (NR). There were 44 children
that received ART through an open-label, phase I/II clinical trial
that evaluated the pharmacokinetics, safety, and antiviral activity of combination antiviral therapies initiated under 2 years of
age (Pediatric AIDS Clinical Trials Group Protocol [PACTG]
356; clinical trials NCT00000872 [16]); 2 were treated by open
prescription. Specimens were collected from HIV-1–infected
participants from 1995 through 2005 at clinical sites throughout the United States and Puerto Rico. Virologic responders
were defined as HIV-1–infected children who achieved plasma
HIV-1 RNA levels of <400 copies/ml by 48 weeks of therapy and
sustained plasma HIV-1 RNA <50 copies/ml through at least 96
weeks; 4 children who were classified as responders experienced
a viral rebound (RNA > 50 copies/ml) and 1 child experienced
a viral blip (a single value of 106 copies/ml) after 96 weeks on
ART. Ab decline estimates in virologic responders were calculated from samples obtained prior to 96 weeks of study. Virologic
non-responders (NR: 10 ET and 14 LT) were children who did
not achieve undetectable viral loads within the first year of ART
(n = 19) or who initially suppressed viral replication but experienced a virologic rebound between 48 and 96 weeks of ART
(n = 5). HIV-1–infected children were studied prior to ART initiation and at 6 months, 1 year, 2 years, and 4 years following
ART initiation. We studied 20 HIV-1–uninfected children born
to HIV-1–infected women (seroreverters [SR]), with samples
obtained at birth and at 6 months, 1 year, and 2 years of age; the
study of SR beyond 2 years of age was not possible, since they
were discharged from routine follow-up for HIV-1 infection if
found to be uninfected by 2 years of age. Institutional Review
Boards at the University of Massachusetts Medical School and
at each clinical site approved this study, and informed consent
was obtained from the children’s guardians prior to enrollment.
Quantitation of HIV-1–specific Antibodies

Ab levels to HIV-1 envelope (gp160, gp41), gag (capsid, p24;
matrix, p17), reverse transcriptase (RT; p66/51), and integrase (p31) were quantified in acid citrate dextrose, heparin,
or ethylenediaminetetraacetic acid-anticoagulated plasma
(Becton-Dickinson Vacutainers, Mountain View, California) by
enzyme-linked immunosorbent assay (ELISA) [17]. The 12-well
high-binding ELISA strips were coated with recombinant proteins: 10ng p24 (Immune Tech, New York, New York) or p17
(Abcam, Cambridge, United Kingdom); or 12.5ng p31 (Abcam),
gp41 (Abcam), gp160 (My Biosource, San Diego, California), or
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RT (Avioq, Research Triangle Park, North Carolina). The 5-point
standard curves were prepared by serially diluting known quantities of HIV-1 p24, gp41, gp160, and RT polyclonal antibodies
(ImmunoDx, Woburn, Massachusetts) in sample buffer. The lack
of available reliable human anti-p17 or anti-p31 mono- or polyclonal antibodies precluded the generation of standard curves for
these proteins. Individual ELISA assays were performed on 1:100
dilutions of pooled plasma samples from HIV-positive (positive
control) and HIV-negative (negative control) individuals, as
well as from the study cohort; in the event that a 1:100 dilution
value fell outside the standard curve linear range, additional 1:10,
1:1000, or 1:10 000 dilutions were run. Absorbance at 405 nm
was measured (Biotek, Winooski, Vermont) and samples were
considered positive if their optical densities (OD) were greater
than 2 standard deviations from the mean OD of a pooled, HIVnegative control (run in triplicate). Quantitative measures of p24,
gp41, gp160, and RT antibodies were determined by extrapolation of OD measurements of standard curve values. Results for
p17 and p31 are reported as OD405nm values, since standard curves
were not generated for these proteins. This approach resulted in
limits of detection (LODs) (dynamic ranges), as follows: p24, 0.1
ug/ml (0.15–125 000ug/ml); gp41, 0.4 ug/ml (0.6–50 000ug/ml);
gp160, 0.1 ug/ml (0.2–50 000ug/ml); RT, 0.1 ug/ml (0.2–3100ug/
ml); p31, 0.06 OD405nm (0.299–2.000 OD405nm); p17, 0.06
OD405nm (0.152–2.000 OD405nm). The lower limit of the
dynamic range was used as the lowest possible value in all calculations. Assay validation using positive controls, negative controls, and individual plasma samples from 5 HIV+ individuals
(20 total samples) showed 90% reproducibility.
Quantitation of Viral Replication and HIV-1 DNA Persistence

Plasma HIV-1 RNA loads were measured using either the Roche
Standard (LOD <400 copies/ml) or UltraSensitive (LOD <50 copies/ml) AMPLICOR HIV-1 MONITOR kits Version 1.5 (Roche
Diagnostics, Indianapolis, Indiana). PBMC HIV-1 total DNA
levels were quantified just prior to initiation of ART and yearly
for 4 years in 21 viral responders and in 8 viral non-responders,
as previously described [10].
Statistical Analyses

Analyses used the software Stata (v13, StataCorp). We used
a 1-way analysis of variance with a post hoc Sidak to compare group Ab levels. Correlations were calculated using the
Spearman rho. Repeated HIV-1–specific Ab levels collected
longitudinally were tested with linear mixed-regression
models to estimate the relative decline rates in each group
through 15 months (data through 12 months with a sample window of 3 months; mean of 3 data points per participant). Post-estimation contrasts compared the decline rates
between groups. Generalized linear models (ordinary least
squares regression for continuous data and logistic regression
for binary outcomes) were fit to test for the association of Ab

levels with plasma HIV-1 RNA copies/ml or HIV-1 DNA copies per million PBMC, using samples obtained at >12 months
of age and adjusting for potentially-confounding covariates.
Regression coefficients were plotted with coefplot [18]. All statistical tests were 2-sided; P < .05 was considered statistically
significant.

RESULTS
Study Cohort

We studied 66 children aged 0 to 24 months, who were grouped
by HIV-1 infection status, age at ART initiation (ET or LT),
and response to ART (responder or non-responder; Table 1).
There was no difference in the log baseline HIV-1 RNA levels
between the ET-R, LT-R, and NR groups (medians 5.4, 4.8, and
5.5, respectively; P = .6). The log HIV-1 DNA at baseline was
similar across the ET-R, LT-R, and NR groups (medians 3.0, 3.7,
and 3.8, respectively; P = .4).
Baseline Antibody Levels

Baseline anti-gp160, -RT, -p24, and -p17 Ab levels were similar
across all groups (Table 2). Baseline anti-gp41 Ab levels were
significantly higher in the SR group than in the ET-R, LT-R, and
NR groups (P = .002); baseline anti-p31 Ab levels were significantly higher in the SR group than in the LT-R (P = .008) and NR
(P = .04) groups. Baseline age was inversely correlated with Ab
levels to RT (rho = 0.34, P = .007), gp41 (rho = -0.35, P = .005),
p31 (rho = -0.45,P < .001), and p17 (rho = -0.26,P = .04). Baseline
gp160 and gp41 Ab levels were highly correlated (rho = 0.68;
P < .001). In young children with continued HIV-1 replication, Ab levels to gp160 and gp41 initially appeared to decrease
from baseline until around age 4–5 months, after which levels
increased (data not shown).
Table 1.

Plasma HIV-1 Antibody Clearance Rates in HIV-1–uninfected Infants

We measured HIV-1 Ab in serial plasma samples from HIV-1–
uninfected infants born to HIV-1–infected women in order to
estimate the decay rates of passively-acquired maternal antibodies and to estimate the time to clearance from the circulation. The decline rate in gp41-specific Ab was faster (-0.25
log ug/ml /month) than in all other Ab specificities (Table 2).
Using the model estimates for the Ab decline in the SR group,
the estimated time to clearance of maternal Ab in the absence
of an HIV-1 infection was calculated to be 10.9 months for
p17, 11.7 months for p31, and 12.4–12.9 months for gp160,
RT, gp41, and p24 (Table 2). Time estimates are based on the
model parameters and do not suggest that all SR were negative
by the estimated time, but rather approximate the time when
the model fit crossed the assay cutoff.
Plasma HIV-1 Antibody Decay Rates in HIV-1–infected Children on
Antiretroviral Therapy

Over the first 15 months of the study, HIV-1 Ab decline rates in
the ET-R group were similar to the SR group for all Ab specificities, with the exception that the decline rate of p17 Ab levels in
ET-R group was slower than in the SR group (P = .01; Table 2,
Figure 1). The estimated time to clearance of all antibodies in
ET-R varied by specificity, and ranged from 12 to 21 months
(Table 2). The estimated age at the clearance of antibodies in
ET-R was similar to the estimated age of clearance for the SR
for all specificities, except for p24 (20.6 months vs 12.9 months,
respectively) and p17 (16.6 months vs 10.9 months, respectively). By contrast, Ab decline rates in the LT-R group and the
NR group were significantly different (slower decline or no decline) from the SR group for all tested Ab specificities (P < .001
for all comparisons). Ab decline rates in the LT-R group and
the NR group were significantly different from the ET-R group
for most Ab specificities (P < .001); an exception was that the

Study Cohort at Baseline: Pre-therapy Viral Load, CD4 Percentage, and Therapeutic Regimens

Cohort

ET Respondersa

SeroReverters

LT Respondersa

Non-responders

n

20

14

8

24

Age, mos

0 (0–0)

1.8 (1.4–2.3)

9.5 (5.7–13.4)

3.8 (2.6–7.5)

log10 plasma HIV-1 RNA,
copies/ml

N/A

5.4 (5.2–5.6)

4.8 (4.7–5.7)

5.5 (4.7–6.0)

log10 proviral DNA,
copies/million PBMCs

N/A

3.0 (2.7–3.4)
n = 13

3.7 (3.0 - 4.0)
n=8

3.8 (3.5–3.9)
n=8

CD4 %

49
(43–59)

38 (28 - 48)

35 (27 - 42)

35 (27–46)

Therapeutic regimens

N/A

10 (2 NRTIs + 1 NNRTI + 1 PI)
2 (3 NRTIs + 1 NNRTI)
1 (2 NRTIs + 1 NNRTI)

5 (2 NRTIs + 1 NNRTI + 1 PI)
2 (3 NRTIs + 1 NNRTI)
1 (2 NRTIs + 1 NNRTI)

8 (2 NRTIs + 1 NNRTI + 1 PI)
7 (3 NRTIs + 1 NNRTI)
9 (2 NRTIs + 1 NNRTI)

Age in mos at viral
suppression

N/A

4.3 (3.5–5.6)

14.8 (8.4–21.7)

N/A

Values are provided as medians with 25th and 75th percentiles (interquartile range).
Abbreviations: ART, antiretroviral therapy; ET, early therapy; HIV, human immunodeficiency virus; LT, late therapy; N/A, not applicable; NNRTI, non-nucleoside reverse-transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; PBMC, peripheral blood mononuclear cell; PI, protease inhibitor.
a

Responders were defined as study subjects who achieved a viral load of <400 copies/ml by 48 weeks of ART therapy and whose peripheral blood HIV-1 RNA levels remained under assay
detection limits through 4 years of ART.
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1.5
(0.6–1.6)

3.2
(2.5–3.5)

1.6
(0.61–2.1)

1.5
(1.4–1.6)

1.2
(0.4–1.9)

RT
log, ug/ml

gp41
log, ug/ml

p24
log, ug/ml

p31, OD

p17, OD

0.9
(0.4–1.1)

1.3
(0.8–1.5)

1.9
(1.7–2.2)

2.2
(1.87–2.7)

1.4
(0.3–1.5)

1.5
(0.9–1.6)

ET-R

0.5
(0.3–0.8)

0.4
(0.3–1.5)

1.4
(0.4–1.7)

2.1
(1.6–2.6)

-0.7
(-0.7–1.7)

1.6
(0.7–1.9)

LT-R

0.9
(0.3–1.4)

0.9
(0.4–1.5)

1.7
(1.1–1.9)

2.4
(1.6–2.8)

0.5
(-0.05–1.2)

1.4
(1.0–1.7)

NR

-0.08
(-0.10, -0.06)

-0.09
(-0.10, -0.07)

-0.17
(-0.19, -0.14)

-0.25
(-0.28, -0.21)

-0.14
(-0.17, -0.11)

-0.19
(-0.22, -0.16)

SR

-0.04
(-0.07, -0.02)

-0.08
(-0.10, -0.06)

-0.14
(-0.18, -0.11)

-0.22
(-0.26, -0.18)

-0.15
(-0.20, -0.10)

-0.18
(-0.21, -0.15)

ET-R

-0.03
(-0.04, -0.01)

-0.01
(-0.03, 0.00)

-0.04
(-0.07,-0.01)

-0.04
(-0.06,-0.02)

-0.05
(-0.09, -0.01)

-0.04
(-0.05, -0.02)

LT-R

NR

0.005
(-0.01, 0.02)

0.008
(-0.01, 0.03)

0.02
(0.00, 0.05)

-0.003
(-0.03, 0.03)

0.005
(-0.02, 0.03)

-0.003
(-0.03, 0.02)

Ab Decay Rate, as Units/Months With 95% CIb

ET P = .01
LT P < .001
NR P < .001

ET P = .80
LT P < .001
NR P < .001

ET P = .24
LT P < .001
NR P < .001

ET P = .53
LT P < .001
NR P < .001

ET P = .87
LT P < .001
NR P < .001

ET P = .91
LT P < .001
NR P < .001

Compared to SR
(Reference)

Slopes with 95% CIs.

Estimate based on linear regression model parameters.

c

b

Median with interquartile range.

a

Abbreviations: Ab, antibody; CI, confidence interval; ET, early therapy; LT, late therapy; NR, viral non-responders; OD, optical densities; R, viral responders; SR, seroreverters; RT, reverse transcriptase.

1.8
(1.2–2.2)

gp160
log, ug/ml

SR

Baselinea

Human Immunodeficiency Virus-1–specific Antibody Levels at Baseline With Antibody Decay Rates

Antibody Specificity

Table 2.

10.9

11.7

12.9

12.8

12.7

12.4

Age at Clearance-SR,
in Monthsc

16.6

11.6

20.6

12.2

12.9

12.4

Age at ClearanceET-R, in Monthsc

18

24

RT

0

6

12
Age (months)

18

24

p31

0

6

12
Age (months)

log Quant Ab (ug/ml)
−1 0 1 2 3 4

12
Age (months)

log Quant Ab (ug/ml)
−1 0 1 2 3 4

6

gp41

0

6

18

24

12
Age (months)

18

24

18

24

18

24

p24

0

6

12
Age (months)

p17

Quant Ab (OD)
0 .5 1 1.5 2

log Quant Ab (ug/ml)
−1 0 1 2 3

0

Quant Ab (OD)
0 .5 1 1.5 2

log Quant Ab (ug/ml)
−1 0 1 2 3

gp160

0

6

12
Age (months)

Figure 1. Human immunodeficiency virus (HIV)-1–specific antibody (Ab) decay rates in HIV-1–uninfected infants born to HIV-1–infected women (SR) in ET-R and LT-R groups.
Quantitative (Quant) Ab levels of HIV-1 gp160, gp41, RT, p24, p31, and p17 in SR, ET-R, and LT-R children over the first 24 months of age. Ab decline rates, calculated over
the first 15 months, in the ET-R group are similar to the SR group for all Ab specificities, except for p17 (P = .01). Fitted lines for the SR and ET-R groups were calculated with
parameters from the linear mixed effects model. SR are shown as blue circles; ET-R as red squares; and LT-R as black, hollow squares. Abbreviations: Ab, antibody; ET, early
therapy; HIV, human immunodeficiency virus; LT, late therapy; OD, optical densities; Quant, quantitative; R, viral responders; SR, seroreverters.

p17-specific Ab decline in the LT-R and ET-R groups were similar (P = .28), while the p17 Ab decay rate in the NR was significantly slower than in the ET-R group (P = .001). Ab levels
in the NR group did not decline, with estimated slopes near 0
(Table 2, individual points for the NR group not displayed in
Figure 1). There were 4 children who initially suppressed HIV-1
replication, experienced a rebound in their viral loads after 96
weeks of ART, and also experienced a rebound in all Ab levels
(data not shown).
Association of Quantitative Antibody Levels With Plasma HIV-1 RNA
Levels and Circulating Cell–associated HIV-1 DNA Levels

We used a linear regression model to predict HIV-1 RNA using
Ab levels obtained after 12 months of age for each HIV-1 specificity tested, except gp41 (highly correlated to gp160): adjusting for age accounted for 62% of the variance in HIV-1 RNA
(F[6,134] = 36; P < .001; R2 = 0.62). Ab levels to gp160, p31,
and p17 were significant predictors in the model (Figure 2).
Ab levels to p31 and p17 were associated with higher plasma

HIV-1 RNA levels (F[3,138] = 66; P < .001; R2 = 0.59;
p31 β = 0.95; p17 β = 0.84), and a logistic model estimated
that a unit increase in p31 Ab was associated with a 14-fold
increase in the odds of an RNA level >50c/ml (P < .001). The
estimated probability of detectable HIV-1 RNA based on Ab
levels of p31, derived from the logistic regression model, is
shown in Figure 2.
A model developed to predict circulating HIV-1 DNA levels using Ab specificities, excluding gp41 and adjusting for age,
accounted for 41% of the variance in HIV-1 DNA (F[6,61] = 7.1;
P < .001; R2 = 0.41, Figure 2). In children over 12 months of
age, gp160 Ab levels predicted circulating HIV-1 DNA levels
(F[2,65], P < .001; R2 = 0.37; β = 0.51). A logistic model using
gp160-specific Ab levels estimated that each unit increase in a
log gp160 Ab was associated with a 6-fold increase in the odds
of an HIV-1 DNA level >1000 (P < .001). The estimated probability of an HIV-1 DNA level > 1000 copies/million PBMC
based on Ab levels of gp160 derived from the logistic regression
model is shown in Figure 2.
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A

B
1

HIV−1 RNA (c/ml)

Pr(HIV−1 RNA > 50 c/ml)
.3 .4 .5 .6 .7 .8 .9

0.2

gp160 ELISA (log ug/ml)
0.1

RT ELISA (log ug/ml)

0.0

p24 ELISA (log ug/ml)

0.7

.2

p31 ELISA (OD)

0

.1

0.6

p17 ELISA (OD)

C

−0.5

0.0

0.5

1.0

HIV−1 DNA (c/million PBMC)
0.6

gp160 ELISA (log ug/ml)
−0.2

RT ELISA (log ug/ml)

0.1

p24 ELISA (log ug/ml)

0.3

p31 ELISA (OD)
−0.4

.5

−1

0

D

1
p31 ELISA (OD)

1.5

2

0

p17 ELISA (OD)

0
Pr(HIV−1 DNA > 1000 c/million PBMC)
.1 .2 .3 .4 .5 .6 .7 .8 .9 1

−1.0

−1.0

−0.5

0.0

0.5

1.0

1
2
gp160 ELISA (log ug/ml)

3

Figure 2. Prediction of human immunodeficiency virus (HIV)-1 RNA and DNA based on linear and logistic models using quantitative antibody levels as predictors.
A, Coefficient plot: coefficients and the 95% confidence intervals for the antibody (Ab) specificities, derived from a linear regression model predicting HIV-1 RNA levels (c/ml)
from Ab levels. Bars which do not cross the line at 0 indicate a significant predictor. Model results: F(6,134) = 36; P < .001; R2 = 0.62. B, The estimated probability of detectable
HIV-1 RNA (>50 c/ml) based on Ab levels of p31 derived from the logistic model. C, Coefficient plot: coefficients and the 95% confidence interval for the Ab specificities,
derived from a linear regression model predicting HIV-1 DNA levels (c/million peripheral blood mononuclear cell) from Ab levels. Bars which do not cross the line at 0 indicate a significant predictor. Model results: F(6,61) = 7.1; P < .001; R2 = 0.41. D, The estimated probability of HIV-1 DNA > 1000 based on Ab levels of gp160 derived from the
logistic model. Abbreviations: Ab, antibody; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; OD, optical densities; PBMC, peripheral blood
mononuclear cell; Pr, probability; RT, reverse transcriptase.

DISCUSSION

We and others have previously shown that ART initiation in children prior to 3–6 months of age allows for the long-term control
of HIV-1 replication and limits residual HIV-1 reservoirs [5, 6].
Younger ages at ART initiation, more intense ART regimens, and
the absence of resistance mutations were related to virologic suppression [16]. Children who rapidly suppress HIV-1 replication
after early (<3 months) ART initiation commonly lack persistent
HIV-1–specific Ab responses [3, 12, 14] and have lower circulating HIV-1 DNA levels [3, 10, 11, 19]. We have previously reported
lower PBMC-associated HIV-1 DNA levels in early-treated, virally-suppressed children with negative or indeterminate Western
blots [15]. Using data and repository samples from a well-characterized early ART cohort [16], we evaluated whether quantitative
HIV-1 Ab levels might predict levels of HIV-1 RNA and DNA in
children on ART.
1730 • CID 2019:68 (15 May) • McManus et al

Because maternal IgG antibodies are passively transferred
from women to their infants during the last trimester of pregnancy [20, 21], all children born at term to HIV-1–infected
women are seropositive. Baseline age correlated inversely with
Ab levels. Moreover, HIV-1–infected children who initiated
ART prior to 3 months of age and who suppressed viral replication by 48 weeks experienced Ab decline rates similar to those
in uninfected children born to HIV-1–infected women for all
Ab specificities, except p17. This suggests little de novo IgG production by the infant over the first several months of age. From
these data, it is difficult to determine exactly when de novo Ab
production to HIV-1 proteins begins; however, baseline Ab data
over the range of ages studied (0–24 months) demonstrate an
increase in antibodies to gp160 and gp41 at around 4–5 months
of age (data not shown), suggesting the active production of
these antibodies. In contrast, antibodies to most HIV-1 proteins

are detected in adults within 3–4 weeks of infection; antibodies to p31 take longer and are produced around 7 weeks after
detectable viremia [22]. The apparent delay in the robust production of HIV-1 antibodies in infants, despite high levels of
HIV-1 replication in early infections, is notable, and could be
due to a lack of CD4+ T-cell help in the face of high levels of
HIV-1 replication.
In our study, most HIV-1–uninfected children born to
HIV-infected women cleared maternal antibodies at around
13 months of age, although prior reports indicate that passively-transferred maternal antibodies may persist in the circulation of uninfected infants up to 18 months [23, 24]. Our data
suggest that antibodies detected after 12–13 months of age are
largely generated in response to the viral replication and antigen
production associated with infection.
In untreated HIV-1–infected adults, anti–HIV-1 Ab levels are
stable over time and correlate with viral loads [25]. Anti–HIV-1
Ab levels decline but do not totally clear with the suppression
of HIV-1 replication on ART; higher levels of HIV-1–specific
antibodies on suppressive therapy are associated with later
initiations of ART after infection and with higher cell-associated DNA and RNA levels. HIV-1–specific Ab persistence after
virologic suppression on ART may be stimulated by low levels
of ongoing viral replication or the production of translationally-competent HIV-1 transcripts [26].
Our study suggests that in children older than 1 year of age,
anti-p31 and anti-p17 IgG Ab levels may be good markers for ongoing replication, while Ab levels to gp160 could serve as a marker for
PBMC-associated HIV-1 DNA levels. In adults, Lee and colleagues
reported that anti-p17 Ab levels were associated with integrated
HIV-1 DNA levels in resting CD4+ T-cells [27]. A recent pediatric
study that examined the relationship between anti-gp41 antibodies
and peripheral blood HIV-1 DNA levels found that lower levels of
antibodies were associated with a younger age at ART initiation;
however, there was no significant correlation between anti-gp41
Ab levels and peripheral blood HIV-1 DNA levels [28]. The difference in findings between the latter study and ours may be related to
the older age at ART initiation (median age 3.3 years) in that study,
or the different methods used to quantitate the total cell-associated
HIV-1 DNA levels.
Our study included a relatively small number of children
from the United States and Puerto Rico who initiated ART
within 2 years of birth. The results of the prediction models may
be limited to children who initiate ART relatively soon after primary infection, and may not be broadly applicable to all HIV-1–
infected children. We used previously-measured cell-associated
HIV-1 DNA levels and only had HIV-1 DNA data for a limited
number (8) of non-responders; nevertheless, we expect that the
inclusion of a larger number of children with detectable viremia, high HIV-1 DNA levels, and relatively high Ab levels would
further strengthen the observed association. Larger studies that
include participants with more diverse ages at ART initiation

and various HIV-1 subtypes will be important to more generally evaluate the utility of HIV-1 Ab levels as markers for viral
replication and reservoir size. Due to the limited blood volumes
available, we did not include other factors, such human leukocyte antigen genotyping, which have been reported to influence
the generation of antibodies following early ART therapy [29].
A recent study suggests that HIV-specific IgG3 antibodies may
be predictors of spontaneous controllers [30]. We did not investigate IgG subclasses, but doing so may elucidate specific combinations of IgG subclasses that might be good markers for viral
replication or persistence.
In summary, even with these limitations, our data suggest
that HIV-1–specific Ab levels may be useful markers for screening children on ART for viral suppression or for low residual
cell-associated HIV-1 DNA levels. This may be particularly useful for screening early-treated children on ART for therapeutic
vaccines and other protocols aimed at achieving HIV-1 remission. Since the measurement of quantitative HIV-1 Ab levels
requires small blood volumes and is generally more rapid, less
expensive, and less technically-intensive than the measurement
of HIV-1 nucleic acids, the measurement of quantitative antibodies may also be useful for screening for virologic suppression and HIV-1 DNA persistence in early-treated children in
limited-resource settings.
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